H I Hurwitz

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors
    Herbert I Hurwitz
    Division of Hematology and Oncology, Duke University Medical Center, P O Box 3052, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 59:139-47. 2007
  2. pmc A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)
    Herbert Hurwitz
    Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA
    Oncologist 17:937-46. 2012
  3. pmc A phase I study of ABT-510 plus bevacizumab in advanced solid tumors
    Hope E Uronis
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Med 2:316-24. 2013
  4. ncbi request reprint Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events
    Herbert Hurwitz
    Duke University Medical Center, Durham, North Carolina 227710, USA
    Semin Oncol 33:S26-34. 2006
  5. doi request reprint The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer
    Herbert I Hurwitz
    Duke University Medical Center, Division of Hematology and Oncology, Durham, NC 27710 0001, USA
    Oncologist 14:22-8. 2009
  6. ncbi request reprint Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer
    Herbert Hurwitz
    Division of Hematology Oncology, Duke University Medical Center, P O Box 3052, Durham, NC 27710, USA
    Clin Colorectal Cancer 4:S62-8. 2004
  7. ncbi request reprint Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
  8. ncbi request reprint Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
    S N Holden
    University of Colorado Cancer Center, Aurora, CO, USA
    Ann Oncol 16:1391-7. 2005
  9. ncbi request reprint Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer
    Herbert I Hurwitz
    Department of Medical Oncology and Transplantation, Room 25132, Morris Building, Box 3052, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 23:3502-8. 2005
  10. ncbi request reprint Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer
    Herbert Hurwitz
    Duke University Medical Centre, Durham, N C 27710, USA
    Oncology 69:17-24. 2005

Research Grants

Detail Information

Publications55

  1. ncbi request reprint A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors
    Herbert I Hurwitz
    Division of Hematology and Oncology, Duke University Medical Center, P O Box 3052, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 59:139-47. 2007
    ....
  2. pmc A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)
    Herbert Hurwitz
    Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA
    Oncologist 17:937-46. 2012
    ..Multiple studies have shown that the addition of bevacizumab to 5-fluorouracil-based chemotherapy is active and well tolerated...
  3. pmc A phase I study of ABT-510 plus bevacizumab in advanced solid tumors
    Hope E Uronis
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Med 2:316-24. 2013
    ..Data suggest that continued evaluation of combination antiangiogenesis therapies may be clinically useful. ..
  4. ncbi request reprint Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events
    Herbert Hurwitz
    Duke University Medical Center, Durham, North Carolina 227710, USA
    Semin Oncol 33:S26-34. 2006
    ..Close patient monitoring, especially in patients who are at greater risk of adverse events, is important...
  5. doi request reprint The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer
    Herbert I Hurwitz
    Duke University Medical Center, Division of Hematology and Oncology, Durham, NC 27710 0001, USA
    Oncologist 14:22-8. 2009
    ..We conducted additional analyses to better describe the clinical benefit of bevacizumab treatment in mCRC relative to K-ras mutation status...
  6. ncbi request reprint Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer
    Herbert Hurwitz
    Division of Hematology Oncology, Duke University Medical Center, P O Box 3052, Durham, NC 27710, USA
    Clin Colorectal Cancer 4:S62-8. 2004
    ..Bevacizumab plus 5-FU is also a highly active first-line regimen. The role of bevacizumab with other first-line combination regimens, as well as its activity in the second-line setting, is now being determined by ongoing clinical trials...
  7. ncbi request reprint Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy...
  8. ncbi request reprint Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
    S N Holden
    University of Colorado Cancer Center, Aurora, CO, USA
    Ann Oncol 16:1391-7. 2005
    ..The safety, tolerability and pharmacokinetics of ZD6474 were assessed in a phase I dose-escalation study of patients with advanced solid tumors...
  9. ncbi request reprint Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer
    Herbert I Hurwitz
    Department of Medical Oncology and Transplantation, Room 25132, Morris Building, Box 3052, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 23:3502-8. 2005
    ..Here, we describe efficacy and safety results for the third patient cohort in this trial, who received BV combined with FU/LV, and compare them with results for concurrently enrolled patients who received IFL...
  10. ncbi request reprint Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer
    Herbert Hurwitz
    Duke University Medical Centre, Durham, N C 27710, USA
    Oncology 69:17-24. 2005
    ..Ongoing trials of bevacizumab in combination with standard first-line chemotherapy regimens will evaluate bevacizumab's potential in a range of cancer types. ...
  11. doi request reprint Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies
    Herbert I Hurwitz
    Duke University Medical Center, Division of Hematology and Oncology, PO Box 3052, Durham, NC 27710 0001, USA
    J Clin Oncol 29:1757-64. 2011
    ..Thromboembolism is a major source of morbidity and mortality in patients with cancer. The contribution of anti-vascular endothelial growth factor therapy to these events remains controversial...
  12. ncbi request reprint Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report
    Herbert I Hurwitz
    Duke University Medical Center, Durham, NC 27710, USA
    Clin Colorectal Cancer 6:66-9. 2006
    ..Throughout most of their disease course, these patients maintained a good quality of life, with some adjustments of chemotherapy doses because of side effects. Bevacizumab was generally well tolerated in long-term use...
  13. ncbi request reprint New combinations in metastatic colorectal cancer: what are our expectations?
    Herbert Hurwitz
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncologist 10:320-2. 2005
  14. ncbi request reprint Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas
    R R White
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Surg Oncol 8:758-65. 2001
    ..Survival after neoadjuvant CRT and resection appears to be at least comparable to survival after resection and adjuvant (postoperative) CRT...
  15. ncbi request reprint A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon
    Brian G Czito
    Department ofRadiation Oncology, Duke University Medical Center, Durham, NC, USA
    Int J Radiat Oncol Biol Phys 58:779-85. 2004
    ..We addressed the safety of oral eniluracil and 5-FU combined with preoperative radiotherapy and determined the recommended Phase II dose and dose-limiting toxicity in patients with locally advanced rectal and colon cancer...
  16. ncbi request reprint Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Am Coll Surg 206:96-106. 2008
    ..The objective of this retrospective study was to determine if addition of bevacizumab to iri/oxal preoperative chemotherapy increases morbidity after hepatic resection...
  17. ncbi request reprint The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Gastrointest Cancer 32:1-6. 2002
    ..Autologous dendritic cells (DCs) loaded with tumor antigens are particularly potent at inducing tumor antigen-specific immune responses...
  18. ncbi request reprint Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer
    Rebekah R White
    Department of Surgery, Duke University Medical Center, Box 3118, Durham, North Carolina 27710, USA
    Ann Surg Oncol 12:214-21. 2005
    ..We hypothesized that histological responses to CRT would be significant prognostic factors in patients undergoing neoadjuvant CRT followed by resection...
  19. doi request reprint Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials
    Fairooz F Kabbinavar
    Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, 2333D PVUB MC 705907, 10945 Le Conte Ave, Los Angeles, CA 90095 7059, USA
    J Clin Oncol 27:199-205. 2009
    ....
  20. doi request reprint Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer
    Fairooz F Kabbinavar
    Division of Hematology Oncology, University of California at Los Angeles, California 90095 7059, USA
    Oncologist 13:1021-9. 2008
    ....
  21. doi request reprint Phase I trial of pazopanib in patients with advanced cancer
    Herbert I Hurwitz
    Duke University Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 15:4220-7. 2009
    ....
  22. ncbi request reprint Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors
    Elizabeth Dugan
    Duke University Medical Center, Durham, NC, 27710, USA
    Anticancer Res 29:5149-53. 2009
    ..To determine the maximally tolerated dose (MTD), recommended phase II dose (RPTD) and toxicity profile of gemcitabine plus irinotecan combination...
  23. ncbi request reprint A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors
    Elizabeth Dugan
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Anticancer Res 30:1251-6. 2010
    ..The aim of this study was to determine the maximally tolerated dose, recommended phase II dose and toxicity profile of capecitabine plus imatinib mesylate combination...
  24. ncbi request reprint Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    Fairooz Kabbinavar
    Division of Hematology Oncology, University of California Los Angeles, School of Medicine, 90095, USA
    J Clin Oncol 21:60-5. 2003
    ....
  25. doi request reprint Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Box 3247, Durham, NC 27710, USA
    J Gastrointest Surg 13:74-84. 2009
    ..The objective of this retrospective study was to determine the effect of multiagent chemotherapy on long-term survival after resection of CLM...
  26. ncbi request reprint A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 67:1002-7. 2007
    ..The optimal combination of chemotherapeutic agents with RT is undefined. We evaluated a combination of capecitabine, carboplatin, and paclitaxel with RT in a phase I study...
  27. ncbi request reprint Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 68:472-8. 2007
    ..A Phase I trial was undertaken to evaluate the combination of bevacizumab, capecitabine, oxaliplatin, and radiation therapy in patients with rectal cancer...
  28. ncbi request reprint Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy
    Chris R Kelsey
    Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 69:1436-41. 2007
    ..To report patterns of disease recurrence after resection of adenocarcinoma of the duodenum and compare outcomes between patients undergoing surgery only vs. surgery with concurrent chemotherapy and radiation therapy (CT-RT)...
  29. ncbi request reprint A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 70:1066-72. 2008
    ..We evaluated the safety and preliminary efficacy of a combination of UFT/leucovorin, carboplatin, and paclitaxel with RT in a Phase I study of patients with advanced esophageal cancer...
  30. doi request reprint The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
    Takuya Osada
    Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    Cancer Immunol Immunother 57:1115-24. 2008
    ..These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies...
  31. ncbi request reprint Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer
    Chris R Kelsey
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 69:770-6. 2007
    ..To compare a neoadjuvant regimen of cisplatin/5-fluorouracil (5-FU) and concurrent radiation therapy (RT) with paclitaxel-based regimens and RT in the management of operable esophageal (EC)/gastroesophageal junction (GEJ) cancer...
  32. pmc Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer
    Christopher G Willett
    Duke University Medical Center, Durham, NC 27710, USA
    Nat Clin Pract Oncol 4:316-21. 2007
    ..The case presented here is a complete pathological response seen in a patient with extensive and locally invasive carcinoma after receiving this combined treatment...
  33. ncbi request reprint Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions
    Richard M Goldberg
    University of North Carolina, Chapel Hill, Chapel Hill, NC, USA
    Clin Adv Hematol Oncol 3:1-10; quiz 11. 2005
    ..Randomized trials incorporating combination chemotherapy regimens plus both bevacizumab and cetuximab are currently underway, as are preliminary studies withnovel angiogenesis inhibitors...
  34. ncbi request reprint A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Invest 24:9-17. 2006
    ..We addressed the safety of oral eniluracil/5-FU combined with radiation therapy and determined the profile of dose-limiting toxicities and recommended Phase II dose (RPTD) in patients with pancreatic and hepatobiliary cancers...
  35. ncbi request reprint Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 24:656-62. 2006
    ..We initiated two phase I trials assessing the combination of gefitinib, capecitabine, and radiation in patients with localized pancreatic and rectal cancer...
  36. ncbi request reprint Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 62:1030-4. 2005
    ..To better define the role of adjuvant radiation therapy and chemotherapy, a retrospective analysis of the outcome of patients undergoing surgery and adjuvant therapy was undertaken...
  37. ncbi request reprint Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA
    Michael A Morse
    Department of Medicine, Medical Center, Box 3233, Durham, North Carolina 27710, USA
    Cancer Invest 21:341-9. 2003
    ..We conclude that it is feasible and safe to administer mRNA-loaded DC to patients with advanced malignancies...
  38. ncbi request reprint Targeted therapy of colorectal cancer: clinical experience with bevacizumab
    Nishan H Fernando
    Department of Medical Oncology and Transplantation, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncologist 9:11-8. 2004
    ..Further phase II/III studies of bevacizumab, administered with 5-fluorouracil plus leucovorin, with or without irinotecan and/or oxaliplatin, in colorectal cancer, are under way...
  39. doi request reprint Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma
    John W Nelson
    Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
    Int J Radiat Oncol Biol Phys 73:148-53. 2009
    ..To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy...
  40. ncbi request reprint Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer
    Nishan H Fernando
    Department of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Semin Oncol 30:39-50. 2003
    ..This review will outline the conceptual basis of anti-angiogenic therapy, discuss the critical role of vascular endothelial growth factor, and summarize the available data on the use of bevacizumab in colorectal cancer...
  41. ncbi request reprint Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer
    Timothy S Collins
    Department of Medical Oncology, Duke University Medical Center, Durham, NC, USA
    Semin Oncol 32:61-8. 2005
    ..This review will outline the biology of angiogenesis in colorectal cancer and discuss the current status of angiogenesis inhibition in its treatment...
  42. ncbi request reprint Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor
    A Craig Lockhart
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:586-93. 2003
    ....
  43. ncbi request reprint New agents in colon cancer
    Herbert I Hurwitz
    Duke University Medical Center, Durham, NC 27701, USA
    Clin Adv Hematol Oncol 1:404-5. 2003
  44. ncbi request reprint Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
    Robert E Martell
    Geriatrics Research, Education and Clinical Center, Veterans Affairs Medical Center and Hematology Oncology Division, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 50:37-45. 2002
    ..We sought to determine whether age, renal function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL...
  45. ncbi request reprint Staging of pancreatic cancer before and after neoadjuvant chemoradiation
    R R White
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Gastrointest Surg 5:626-33. 2001
    ..Following neoadjuvant chemoradiation, restaging CT guides the selection of patients for laparotomy but may overestimate unresectability to a greater extent than does prechemoradiation CT...
  46. ncbi request reprint A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer
    Nan Soon Wong
    Duke University Medical Center, Durham, NC 27710, USA
    Anticancer Res 31:255-61. 2011
    ..This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer...
  47. pmc A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
    Ivy Altomare
    Duke University Medical Center, Durham, North Carolina, USA
    Oncologist 16:1131-7. 2011
    ..A phase I study of bevacizumab plus everolimus demonstrated that the combination is safe; activity was seen in several patients with refractory mCRC...
  48. ncbi request reprint Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
    Fairooz F Kabbinavar
    University of California Los Angeles, Los Angeles, CA, USA
    J Clin Oncol 23:3706-12. 2005
    ..Three randomized clinical studies have evaluated bevacizumab in combination with FU/LV alone. A combined analysis of raw data from these studies was performed to better assess the efficacy of bevacizumab with FU/LV...
  49. ncbi request reprint Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Howard A Burris
    The Sarah Cannon Research Institute, 250 25th Avenue N, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 23:5305-13. 2005
    ....
  50. ncbi request reprint Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab
    William L Ince
    Department of Pathology, Genentech Inc, San Francisco, CA, USA
    J Natl Cancer Inst 97:981-9. 2005
    ..We carried out a retrospective analysis of patients in the trial to evaluate whether mutation status of k-ras, b-raf, or p53 or P53 expression could predict which patients were more likely to respond to bevacizumab...
  51. doi request reprint Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107
    Axel Grothey
    Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:183-9. 2008
    ..As these two superior therapies have differing mechanisms of action, we explored whether the improved survival associated with the superior therapy was dependent on tumor response...
  52. ncbi request reprint Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:4793-9. 2007
    ..We assessed the safety and efficacy of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy...
  53. ncbi request reprint Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer
    Adrian M Jubb
    Department of Pathology, Genentech Inc, South San Francisco, CA, USA
    J Clin Oncol 24:217-27. 2006
    ..The aim of these retrospective subset analyses was to evaluate VEGF, thrombospondin-2 (THBS-2), and microvessel density (MVD) as prognostic factors and/or predictors of benefit from bevacizumab...
  54. ncbi request reprint Angiogenesis pathway inhibitors
    Roy S Herbst
    Department of Cancer Biology, Radiation, University of Texas, MD Anderson Cancer Center, Houston, TX 70030 4009, USA
    Cancer Chemother Biol Response Modif 22:225-45. 2005
  55. ncbi request reprint The role of targeted therapy in the treatment of colorectal cancer
    Richard M Goldberg
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
    ..Additional targeted agents are also being developed and are showing promise in clinical trials...

Research Grants9

  1. Does NO mediate clinical anti-VEGF vascular effects
    Herbert Hurwitz; Fiscal Year: 2004
    ..However, to allow for potential clinical benefit, patients will be permitted to receive ongoing anti-VEGF therapy as deemed appropriate by their physician. ..
  2. NEW CLINICAL BIOMARKER FOR CANCER--WOUND ANGIOGENESIS
    Herbert Hurwitz; Fiscal Year: 2005
    ..4) To evaluate several potential refinements of this normal wound angiogenesis assay in healthy volunteers, and incorporate these refinements in to patient studies involving novel anti-angiogenesis agents. ..
  3. Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity
    Herbert Hurwitz; Fiscal Year: 2007
    ..This work has the potential to improve both the safety and efficacy of this novel class of drugs. ..
  4. Wound Angiogenesis as a Biomarker for Tumor Angiogenesis
    Herbert Hurwitz; Fiscal Year: 2007
    ..Trainees will have specific educational and research experiences, including the development and oversight of several biomarker studies. ..
  5. Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity
    Herbert Hurwitz; Fiscal Year: 2009
    ..This work has the potential to improve both the safety and efficacy of this novel class of drugs. I; ' ..
  6. Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity
    Herbert I Hurwitz; Fiscal Year: 2010
    ..This work has the potential to improve both the safety and efficacy of this novel class of drugs. I;' ..